2018
Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior
Verplaetse TL, Weinberger AH, Ashare RL, Pittman BP, Shi JM, Tetrault JM, Lavery M, McKee SA. Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior. Journal Of Psychopharmacology 2018, 32: 1003-1009. PMID: 29692206, PMCID: PMC6258014, DOI: 10.1177/0269881118767647.Peer-Reviewed Original ResearchConceptsEffects of carvedilolSmoking lapse behaviorAdrenergic antagonistsTobacco cravingSmoking outcomesPhysiologic reactivitySystolic blood pressureNumber of cigarettesNicotine-motivated behaviors× time effectSelf-administration periodEffects of α1Human laboratory modelNicotine-deprived smokersPlacebo groupBlood pressureAdrenergic antagonismMedication conditionClinical indicationsNoradrenergic systemSubsequent smokingHeart rateProperties of drugsSmokingCarvedilol
2017
Effect of doxazosin on stress reactivity and the ability to resist smoking
Verplaetse TL, Weinberger AH, Oberleitner LM, Smith KM, Pittman BP, Shi JM, Tetrault JM, Lavery ME, Picciotto MR, McKee SA. Effect of doxazosin on stress reactivity and the ability to resist smoking. Journal Of Psychopharmacology 2017, 31: 830-840. PMID: 28440105, PMCID: PMC5823502, DOI: 10.1177/0269881117699603.Peer-Reviewed Original ResearchConceptsTobacco cravingCortisol levelsSubsequent ad libitum smokingEffects of doxazosinAd libitum smokingNumber of cigarettesNicotine-motivated behaviorsSmoking lapse behaviorΑ1-adrenergic antagonistNicotine-deprived smokersTitration periodPreclinical findingsSmoking cessationNoradrenergic systemTreatment strategiesDoxazosinSmoking behaviorSmokingHuman laboratoryPhysiologic reactivityPilot studyStress reactivityEffects of stressCigarettesStress imagery
2014
Varenicline, an optional treatment for alcohol dependence syndrome in smokers or non-smokers.
Ebert S, Tetrault J. Varenicline, an optional treatment for alcohol dependence syndrome in smokers or non-smokers. Revue Médicale Suisse 2014, 10: 1893. PMID: 25417365, DOI: 10.53738/revmed.2014.10.445.1893.Peer-Reviewed Original Research
2013
A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self‐administration
Udo T, Harrison EL, Shi J, Tetrault J, McKee SA. A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self‐administration. American Journal On Addictions 2013, 22: 590-597. PMID: 24131167, PMCID: PMC3934424, DOI: 10.1111/j.1521-0391.2013.12014.x.Peer-Reviewed Original ResearchConceptsSelf-administration periodNicotine nasal sprayHeavy drinking smokersNasal sprayNicotine patchAlcohol responsesPriming drinkSerum nicotine levelsPlacebo-controlled studyNicotine replacement therapySubjective alcohol responsesPositive subjective responsesNumber of drinksPlacebo administrationReplacement therapyPriming doseSmoking relapseAlcohol consumptionPlacebo conditionPatch applicationNicotine levelsClinical settingPilot studySmokersSubjective responses
2012
Combining Rapid HIV Testing and a Brief Alcohol Intervention in Young Unhealthy Drinkers in the Emergency Department: A Pilot Study
Edelman EJ, Dinh A, Radulescu R, Lurie B, D'Onofrio G, Tetrault JM, Fiellin DA, Fiellin LE. Combining Rapid HIV Testing and a Brief Alcohol Intervention in Young Unhealthy Drinkers in the Emergency Department: A Pilot Study. The American Journal Of Drug And Alcohol Abuse 2012, 38: 539-543. PMID: 22794939, PMCID: PMC3522092, DOI: 10.3109/00952990.2012.701359.Peer-Reviewed Original ResearchConceptsSexual risk reduction counselingSexual risk behaviorsRisk reduction counselingRapid HIV testingEmergency departmentRisk behaviorsReduction counselingHIV testingAlcohol useUnhealthy drinkersAlcohol consumptionMean age 26 yearsAverage weekly drinksImportant preventive servicesAlcohol Use Disorders Identification Test (AUDIT) scoresUnknown HIV statusRapid HIV testsUnhealthy alcohol useAge 26 yearsBrief alcohol interventionHIV testHIV statusRegular doctorPreventive servicesRisk populations
2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependence